Targeting Methotrexate to Resistant Tumor Cells
Author Information
Author(s): K. Affleck, M.J. Embleton
Primary Institution: Cancer Research Campaign Laboratories, University of Nottingham
Hypothesis
Can monoclonal antibodies be used to overcome methotrexate resistance in tumor cells?
Conclusion
Monoclonal antibody-targeted methotrexate can effectively overcome drug resistance in certain tumor cell lines.
Supporting Evidence
- Four methotrexate-resistant sublines were established from the 791T cell line.
- The conjugates were cytotoxic to both parental and resistant cell lines.
- Resistance was not solely due to overproduction of dihydrofolate reductase.
Takeaway
Scientists found a way to help cancer drugs work better by using special antibodies that help the drugs get into resistant cancer cells.
Methodology
The study involved creating methotrexate-resistant sublines of a cancer cell line and testing the effectiveness of antibody-drug conjugates on these cells.
Limitations
The study's findings may not fully translate to clinical applications due to potential issues with drug distribution in the body.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website